3D Nanotube-in-Micropillar Electrodes Enable Size-Independent Blood Cell Electroporation

Study Background and Research Question

Cellular immunotherapy and mRNA-based interventions in hematologic and oncologic disease depend critically on the efficient delivery of genetic material into target blood cells. Traditional immunotherapy workflows often require complex, multi-step ex vivo manipulations—such as leukapheresis, in vitro expansion, and nucleic acid loading—which are time-consuming, costly, and expose cells to contamination risks. Electroporation offers a non-viral alternative for introducing plasmid DNA or RNA into cells, but its efficiency and cell viability are highly dependent on cell size, type, and orientation within the electric field. This limitation is particularly pronounced in heterogeneous blood samples, which contain a mix of white blood cells, erythrocytes, and other cellular components of varied dimensions and properties. The central research question addressed by Liu et al. (Lab Chip, 2021) is how to achieve robust, size-independent electroporation across diverse blood cell populations, thus improving the practicality and safety of non-viral gene delivery for cell therapy and mRNA-based interventions.

Key Innovation from the Reference Study

The key innovation in this study is the development of a three-dimensional (3D) electrode system, termed the nanotube-in-micropillar array electrode. By leveraging replica molding and infiltration-coating techniques, the researchers created a high-density array of polymer micropillars, partially embedded with vertically oriented carbon nanotubes (CNTs). This architecture enables blood cells, irrespective of their size or orientation, to deform and establish intimate contact with both the top and side surfaces of the micropillars during electroporation. The vertically exposed CNTs maximize the transmembrane potential experienced by each cell, enhancing membrane permeabilization and, consequently, gene delivery efficacy. This design directly addresses the challenge of variable transfection efficiency in heterogeneous blood samples, which has limited the broader adoption of non-viral electroporation in clinical and research settings.

Methods and Experimental Design Insights

The fabrication process involved two major steps: (1) replica molding to create an array of polymer micropillars on a substrate, and (2) infiltration-coating to integrate conductive CNTs, with their protruded ends oriented vertically. This hybrid structure was characterized using scanning electron microscopy (SEM) and impedance spectroscopy to confirm surface morphology and electrical properties. For functional validation, the electrodes were incorporated into a microfluidic chip, allowing precise control over cell loading and electroporation conditions.

Blood samples—both individual cell types (such as isolated white blood cells) and whole blood—were subjected to electroporation with fluorescently labeled plasmid DNA and high-dose RNA probes. Delivery efficiency was assessed by flow cytometry and fluorescence microscopy at multiple time points post-transfection (24 h and 72 h). Cell viability was evaluated in parallel, ensuring that increased transfection did not come at the cost of excessive cytotoxicity.

Protocol Parameters

• Electrode fabrication: Replica molded polymer micropillar arrays; CNTs embedded by infiltration-coating, with vertical exposure confirmed by SEM.
• Electroporation buffer: Standard physiological buffer; cell density and buffer composition adjusted to minimize cytotoxicity.
• Pulse parameters: Voltage and duration optimized for whole blood and isolated cell types; typical field strengths sufficient for rapid membrane permeabilization without compromising viability.
• Transfection assessment: Flow cytometry and fluorescence microscopy at 24 h and 72 h post-electroporation to quantify delivery and expression.
• Cell viability: Assessed immediately after electroporation and at subsequent time points using standard viability dyes.

Core Findings and Why They Matter

The 3D nanotube-in-micropillar system delivered several significant findings:

• High transfection efficiency: In both isolated blood cell types and whole blood, plasmid DNA delivery reached up to 85% at 24 h and 95% at 72 h post-electroporation (Liu et al.), representing a 2.5–3-fold enhancement over conventional planar electrode systems.
• Size independence: Transfection was effective across a broad range of blood cell sizes, including erythrocytes and white blood cells, regardless of random orientation or dispersion within the sample.
• RNA probe delivery: The system efficiently delivered high-dose RNA probes, enabling regulated expression of exogenous and endogenous genes in blood cells—an essential step for both gene regulation and function study and therapeutic mRNA vaccination.
• Cell viability maintained: Despite increased delivery rates, cell viability remained comparable to or better than existing non-viral methods, addressing a common trade-off in electroporation-based techniques.

These outcomes establish the 3D electrode as a robust platform for mRNA delivery and translation efficiency assays, especially in workflows demanding suppression of RNA-mediated innate immune activation (minimized by non-viral, transient delivery), and where poly(A) tail enhanced translation initiation is critical.

Comparison with Existing Internal Articles

Recent internal resources, such as "EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Enhanced Capped mRNA for..." and "Optimizing mRNA Delivery: EZ Cap™ Cy5 EGFP mRNA (5-moUTP)...", focus on the optimization of synthetic mRNA constructs for improved delivery, translation efficiency, and immune evasion. These articles highlight the benefits of using capped mRNAs with Cap 1 structure, 5-methoxyuridine (5-moUTP) modifications, and covalently attached Cy5 labels for real-time quantitative tracking and functional readouts. While the internal resources primarily address the molecular engineering of reporter mRNAs, the reference study by Liu et al. addresses the complementary challenge of delivering such advanced constructs efficiently into blood cells. When used in conjunction, optimized mRNA reagents and advanced electroporation hardware can synergistically improve the fidelity and reproducibility of gene regulation and function studies.

Limitations and Transferability

Despite its robust performance, the 3D nanotube-in-micropillar approach has some limitations. The fabrication process requires specialized microfabrication facilities and quality control to ensure uniform CNT integration and electrode reproducibility. While results for plasmid and RNA probe delivery in blood cells are compelling, further validation in primary human samples, disease-specific contexts, and scaled-up clinical manufacturing is needed. Additionally, long-term effects on cell function and potential off-target impacts of repeated electroporation must be studied before widespread therapeutic application. Transferability to other tissue-derived cell types or in vivo settings will depend on further optimization of electrode geometry and system integration.

Research Support Resources

For researchers seeking to translate these findings into practical workflows, the use of dual-fluorescence reporter mRNAs—such as EZ Cap™ Cy5 EGFP mRNA (5-moUTP) (SKU R1011)—can facilitate quantitative assessment of mRNA delivery and translation in electroporated blood cells. This reagent features a capped, 5-moUTP-modified, Cy5-labeled EGFP mRNA, supporting real-time tracking of uptake and expression in cell-based assays. By combining advanced reagents with size-independent electroporation systems, researchers can more effectively evaluate and optimize gene delivery, immune activation profiles, and functional outcomes in blood cell therapy and mRNA-based research. APExBIO provides detailed protocols and technical support to assist with integration into both discovery and translational workflows.